Open access · CC-BY
via OpenAlex
Alpha-synuclein is increased in erythrocytes in parkinson’s disease cases
Ryan N. Coyle, Anne M. Roberts, Malcolm Kenneth Horne, Christopher James Fowler, Colin Louis Masters, Blaine Russell Roberts
Scientific Reports · 2025 · ▲ 3 citations
Abstract
Abstract Idiopathic Parkinson’s disease (iPD) is the second most common neurodegenerative disease after Alzheimer’s disease (AD). Mutations in the SCNA gene, which encodes the protein alpha synuclein (α-syn), are associated with familial forms of Parkinson's disease (PD). Additionally, Lewy bodies (LBs) rich in α-synuclein are a hallmark of idiopathic Parkinson's disease (iPD) pathology. Unlike AD, there are no effective blood-based diagnostic assays for iPD. Recent studies show that measures of misfolded α-syn in cerebrospinal fluid (CSF) and skin biopsies reflect the diagnosis of iPD. The presence of misfolded α-syn suggests that the altered cellular processes in the brain that lead to aggregated α-syn may also occur in the periphery. However, CSF and skin biopsies are intrusive, highlighting the need for a blood-based diagnostic assay. Erythrocytes are the richest source of α-syn in the body, and we hypothesized that peripheral α-syn changes could be detected in erythrocytes in iPD. To test this hypothesis, we used a targeted liquid chromatography-mass spectrometry (LC-MS) assay, that included 15N-enriched recombinant α-syn as an internal standard. We compared the levels of α-syn in erythrocytes from iPD patients, AD patients, and healthy controls (CN). α-syn concentrations were significantly elevated in iPD (48.1 (29.7) µg*mL-1 of erythrocytes, median (IQR)) compared to CN (36.1 (28.4) µg*mL-1) and no difference was observed in AD (33.5 (18.1) µg*mL-1). Although α-syn levels were significantly elevated in iPD, the receiver operating characteristic (ROC) analysis yielded an area under the curve (AUC) of 0.62, indicating that erythrocytic α-syn levels alone are not sufficient for diagnostic purposes.
◌ CITATION ONLY
Full text is not openly licensed for redistribution here. Read it at the source:
Provenance
- Source
- OpenAlex
- DOI
- 10.1038/s41598-025-11979-8
- Canonical
- link ↗
- Fetched
- 2026-10-27 MST
Cite this
APA
Coyle, R.N., Roberts, A.M., Horne, M.K., Fowler, C.J., Masters, C.L., & Roberts, B.R. (2025). Alpha-synuclein is increased in erythrocytes in parkinson’s disease cases. <em>Scientific Reports</em>. https://doi.org/10.1038/s41598-025-11979-8
Vancouver
Coyle RN, Roberts AM, Horne MK, Fowler CJ, Masters CL, Roberts BR. Alpha-synuclein is increased in erythrocytes in parkinson’s disease cases. Scientific Reports. 2025. doi:10.1038/s41598-025-11979-8.
BibTeX
@article{ryan2025Alphas,
title = {Alpha-synuclein is increased in erythrocytes in parkinson’s disease cases},
author = {Ryan N. Coyle and Anne M. Roberts and Malcolm Kenneth Horne and Christopher James Fowler and Colin Louis Masters and Blaine Russell Roberts},
journal = {Scientific Reports},
year = {2025},
doi = {10.1038/s41598-025-11979-8},
}
Research neighborhood
References, citing works, and semantically nearest findings. Click a node to open it.
Related findings
Movement Disorders 2019
Open access · CC-BY
Comparative study of cerebrospinal fluid α‐synuclein seeding aggregation assays for diagnosis of Parkinson's disease
Movement Disorders Clinical Practice 2017
Open access · OA
The Presence of Alpha‐Synuclein in Skin from Melanoma and Patients with Parkinson's Disease
Journal of Parkinson s Disease 2017
Open access · CC-BY
The Role of Lipids Interacting with α-Synuclein in the Pathogenesis of Parkinson’s Disease
Journal of Neurochemistry 2019
Open access · OA
Parkinson’s disease biomarkers based on α‐synuclein
Qatar Foundation Annual Research Conference (ARC) 2016
Citation only
Alpha-Synuclein Oligomers as a Biomarker Candidate for Parkinson's Disease and Disorders
Global Medical & Health Communication (GMHC) 2022
Open access · CC-BY